• MJHLS Brand Logo

© 2020 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.

Insights

Our Insights series brings you perspectives on biosimilars from key leaders in the field.

The Role of Biosimilars in Oncology

Available Oncology Biosimilars and Their Efficacy
Available Oncology Biosimilars and Their Efficacy
What Are Biosimilars?
What Are Biosimilars?
Are Biosimilars and Biologics Similar?
Are Biosimilars and Biologics Similar?
Can Biosimilars Be Switched?
Can Biosimilars Be Switched?
The FDA Approval of Biosimilars
The FDA Approval of Biosimilars
The FDA Pathway for Interchangeable Biosimilars
The FDA Pathway for Interchangeable Biosimilars
Deciding Which Biosimilar to Use
Deciding Which Biosimilar to Use
How Biosimilars Have Impacted Cancer Treatment
How Biosimilars Have Impacted Cancer Treatment
Patient Access to Biosimilars
Patient Access to Biosimilars
The Economic Impact of Biosimilars
The Economic Impact of Biosimilars
The Role of Insurance Companies and PBMs on Biosimilar Access
The Role of Insurance Companies and PBMs on Biosimilar Access
Formulary Inclusion for Biosimilars
Formulary Inclusion for Biosimilars
Biosimilar Challenges for Providers and Payers
Biosimilar Challenges for Providers and Payers
Educating Patients and Clinicians About Biosimilars
Educating Patients and Clinicians About Biosimilars

Global Perspective on the Effect of Biosimilars

Comparison of Biologics to Biosimilars Versus Generics
Comparison of Biologics to Biosimilars Versus Generics
The BPCIA and the Naming of Biosimilars
The BPCIA and the Naming of Biosimilars
The Approval Process for Biosimilars
The Approval Process for Biosimilars
Considerations for Approving Generics Versus Biosimilars
Considerations for Approving Generics Versus Biosimilars
Interchangeability and Postmarketing Pharmacovigilance of Biosimilars
Interchangeability and Postmarketing Pharmacovigilance of Biosimilars
Experience Prescribing Biosimilars Versus Biologics
Experience Prescribing Biosimilars Versus Biologics
The Impact of Access to Biosimilars
The Impact of Access to Biosimilars
US and EU Biosimilar Pricing and Stakeholder Education
US and EU Biosimilar Pricing and Stakeholder Education
Formulary Approval and Challenges for Payers
Formulary Approval and Challenges for Payers
Prescribing Biosimilars and Educating Patients and Physicians
Prescribing Biosimilars and Educating Patients and Physicians
The Influence of Biosimilars in Cancer Care
The Influence of Biosimilars in Cancer Care
Biosimilars in the Pipeline and Disease Management
Biosimilars in the Pipeline and Disease Management
Outlook on the Future of Biosimilars
Outlook on the Future of Biosimilars
x